Drenth Joost P H
Radboudumc, afd. Maag-, Darm- en Leverziekten, Nijmegen.
Ned Tijdschr Geneeskd. 2014;159:A8556.
If left untreated, hepatitis C infection can lead to hepatitis, liver fibrosis, cirrhosis and hepatocellular carcinoma. Until recently, the standard-of-care was peginterferon with ribavirin. Sofosbuvir is a novel direct antiviral acting agent that targets hepatitis C. Administration of sofosbuvir leads to high cure rates, but is very expensive. Here we question the concept of the value-based pricing of sofosbuvir, and argue that the spiralling price of new drugs leads to an unsustainable healthcare system.
如果不进行治疗，丙型肝炎感染可导致肝炎、肝纤维化、肝硬化和肝细胞癌。直到最近，标准治疗方案还是聚乙二醇干扰素联合利巴韦林。索磷布韦是一种新型的直接作用抗病毒药物，靶向丙型肝炎病毒。使用索磷布韦可带来高治愈率，但价格非常昂贵。在此，我们对索磷布韦基于价值定价的概念提出质疑，并认为新药价格不断攀升会导致医疗保健系统难以为继。
